Evidence map›Paper›PMID 41550252›Full record

ArticleJournal of diabetes and metabolic disorders2026

Inhibitory effects of water chestnut (

Hiroshi Mizuno, Gaku Ishigooka, Denan Jin, Shinji Takai, Teruyo Kida

Abstract read
In one paragraph

Article in Journal of diabetes and metabolic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hiroshi MizunoDepartment of Ophthalmology, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki, Osaka, Japan.
Gaku IshigookaDepartment of Ophthalmology, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki, Osaka, Japan.
Denan JinDepartment of Innovative Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.ORCID 0000-0002-5820-8168
Shinji TakaiDepartment of Innovative Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.ORCID 0000-0001-6196-4477
Teruyo KidaDepartment of Ophthalmology, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki, Osaka, Japan.ORCID 0000-0003-3074-162X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Methods: Seven-week-old SDT rats ( Results: The progression of diabetic cataract was suppressed in the TBE plus lutein group. PCR results revealed that NOX-1 in lenses was significantly suppressed in the TBE plus lutein group ( Conclusion: TBE plus lutein may inhibit the progression of diabetic cataract by increasing antioxidant-related factors rather than suppressing oxidative stress-related factors.

Indexed as

AntioxidantDiabetic cataractLuteinOxidative stressTrapa bispinosa Roxb. extract

Identifiers

PMID41550252
PMCPMC12804548

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.